Market closed
Galecto Inc./$GLTO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Ticker
$GLTO
Sector
Trading on
Industry
Biotechnology
Headquarters
Copenhagen, Denmark
Employees
5
Website
Galecto Inc. Metrics
BasicAdvanced
$3.3M
-
-$18.53
1.19
-
Price and volume
Market cap
$3.3M
Beta
1.19
52-week high
$7.30
52-week low
$2.01
Average daily volume
489K
Financial strength
Current ratio
14.068
Quick ratio
12.578
Long term debt to equity
0.385
Total debt to equity
0.461
Management effectiveness
Return on assets (TTM)
-38.15%
Return on equity (TTM)
-89.03%
Valuation
Price to book
0.23
Price to tangible book (TTM)
0.23
Price to free cash flow (TTM)
-0.155
Growth
Earnings per share change (TTM)
-48.65%
3-year earnings per share growth (CAGR)
-28.75%
Galecto Inc. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Galecto Inc. stock?
Galecto Inc. (GLTO) has a market cap of $3.3M as of April 16, 2025.
What is the P/E ratio for Galecto Inc. stock?
The price to earnings (P/E) ratio for Galecto Inc. (GLTO) stock is 0 as of April 16, 2025.
Does Galecto Inc. stock pay dividends?
No, Galecto Inc. (GLTO) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Galecto Inc. dividend payment date?
Galecto Inc. (GLTO) stock does not pay dividends to its shareholders.
What is the beta indicator for Galecto Inc.?
Galecto Inc. (GLTO) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.